John Devin Peipert, Fengmin Zhao, Ju-Whei Lee, Shu-En Shen, Edward Ip, Nathaniel O'Connell, Ruth C Carlos, Noah Graham, Mary Lou Smith, Ilana F Gareen, Pamela J Raper, Matthias Weiss, Shaji K Kumar, S Vincent Rajkumar, David Cella, Robert Gray, Lynne I Wagner
IMPORTANCE: There is substantial interest in capturing cancer treatment tolerability from the patient's perspective using patient-reported outcomes (PROs). OBJECTIVE: To examine whether a PRO question, item 5 from the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early treatment discontinuation (ETD) due to adverse events. DESIGN, SETTING, AND PARTICIPANTS: This prospective survey study was conducted from February to April 2023...
March 4, 2024: JAMA Network Open